Moderna Inc(MRNA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 5:11 PM ET (Korea 10/28 06:11)
Full metrics table
| Index | NDX, S&P 500 | P/E | - | EPS (ttm) | -7.98 | Insider Own | 8.52% | Shs Outstand | 399.0M | Perf Week | -14.17% |
| Market Cap | 82.95B | Forward P/E | - | EPS next Y | 43.53% | Insider Trans | -2.51% | Shs Float | 365.2M | Perf Month | 5.32% |
| Enterprise Value | 79.10B | PEG | - | EPS next Q | -1.11 | Inst Own | 80.34% | Short Float | 8.93% | Perf Quarter | 281.32% |
| Income | -3.15B | P/S | 37.23 | EPS this Y | -15.98% | Inst Trans | 1.97% | Short Ratio | 1.58 | Perf Half Y | 340.77% |
| Sales | 2.23B | P/B | 12.26 | EPS next 5Y | 26.78% | ROA | -27.43% | Short Interest | 32.60M | Perf YTD | 604.58% |
| Book/sh | 16.94 | P/C | 16.15 | EPS past 3/5Y | - -29.93% | ROE | -39% | 52W High | -18.35% ($254.48) | Perf Year | 679.37% |
| Cash/sh | 12.87 | P/FCF | - | Sales past 3/5Y | -53.32% 19.33% | ROIC | -39.41% | 52W Low | 832.59% ($22.28) | Perf 3Y | 188.94% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -6.22% | Gross Margin | 12.57% | Volatility(W/M) | 15.52% 10.39% | Perf 5Y | -39.05% |
| Dividend TTM | - | EV/Sales | 35.5 | Sales Y/Y TTM | -27.62% | Oper. Margin | -149.01% | ATR (14) | 21.81 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.18 | EPS Q/Q | 7.6% | Profit Margin | -141.43% | RSI (14) | 52.87 | Recom | 3.04 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.29 | Sales Q/Q | 2.11% | SMA20 | -1.42% ($210.77) | Beta | 1.19 | Target Price | $138.47 |
| Payout | - | Debt/Eq | 0.19 | Earnings | 2026/11/6 | SMA50 | 17.57% ($176.73) | Rel Volume | 0.85 | Prev Close | $198.85 |
| Employees | 4700 | LT Debt/Eq | 0.18 | EPS/Sales Surpr. | 3.06% 40.87% | SMA200 | 147.78% ($83.86) | Avg Volume(3M) | 20.62M | Price | $207.78 |
| IPO | 2018/12/7 | Option/Short | Yes/Yes | Trades | 179373 | Volume | 17,502,466 | Change | 4.49% |
A biotech company that develops vaccines and therapeutics based on messenger RNA (mRNA) technology. It became widely known for its COVID-19 vaccine and has been expanding its pipeline to include respiratory vaccines, influenza and latent virus vaccines, as well as personalized cancer therapeutics. It is a representative biotech company with its mRNA platform as its core asset.
Over the past 1 year, on the higher side
18% below its 1-year high.
Traded about as much as usual. That is 85% of its average volume.
Next earnings report: November 6
10 days to go.
MRNA has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -16.0% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $3,723. Peers typically go for $906. Compared with its own 2-year average, it is 402% pricier now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -39.0%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 80.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
LGHT Langar Global HealthTech ETF 0.08% 
FBT First Trust NYSE Arca Biotechnology Index Fund 0.05% 
ULTI REX IncomeMax Option Strategy ETF 0.05% 
IDNA iShares Genomics Immunology and Healthcare ETF 0.04% 
WDNA WisdomTree BioRevolution Fund 0.04% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
MRNX Defiance Daily Target 2X Long MRNA ETF 25M It ranks #3 of 594 in the industry
Based on market cap of $83B.
FAQ
What kind of company is MRNA?
MRNA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of MRNA?
The market cap of MRNA is approximately $83.0B, ranking 204 within its sector.
What is the 52-week high and low for MRNA?
MRNA has recorded a 52-week high of $254.48 and a low of $22.28.
